The Experts below are selected from a list of 120 Experts worldwide ranked by ideXlab platform
Sj Machin - One of the best experts on this subject based on the ideXlab platform.
-
Hextend (R), a physiologically balanced plasma Expander for large Volume use in major surgery: A randomized phase III clinical trial
LIPPINCOTT WILLIAMS & WILKINS, 1999Co-Authors: Tj Gan, Bennett-guerrero E, Phillips-bute B, Wakeling H, Dm Moskowitz, Olufolabi Y, Sn Konstadt, Bradford C, Glass Psa, Sj MachinAbstract:Hestend((R)) (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with alternatives, such as albumin or 6% hetastarch in saline. In a prospective, randomized, two-center study (n = 120), we compared the efficacy and safety of Hextend((R)) versus 6% hetastarch in saline (HES) for the treatment of hypovolemia during major surgery. Patients at one center had a blood sample drawn at the beginning and the end of surgery for thromboelastographic (TEG) analysis. Hextend((R)) was as effective as HES for the treatment of hypovolemia. Patients received an average of 1596 mt of Hestend((R)): 42% received >20 mL/kg up to a total of 5000 mt. No patient received albumin. Hextend((R))-treated patients required less intraoperative calcium (4 vs 220 mg; P < 0.05). In a subset analysis of patients receiving red blood cell transfusions (n = 56; 47%), Hextend((R))-treated patients had a lower mean estimated blood loss (956 mt less; P = 0.02) and were less likely to receive calcium supplementation (P = 0.04). Patients receiving HES demonstrated significant prolongation of time to onset of clot formation (based on TEG) not seen in the Hextend((R)) patients (P < 0.05). No Hextend((R)) patient experienced a related serious adverse event, and there was no difference in the total number of adverse events between the two groups. The results of this study demonstrate that Hextend((R)), with its novel buffered, balanced electrolyte formulation, is as effective as 6% hetastarch in saline for the treatment of hypovolemia and may be a safe alternative even when used in Volumes up to 5 L. Implications: Hextend((R)) (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and a physiological level of glucose. It is as effective as 6% hetastarch in saline for the treatment of hypovolemia but has a more favorable side effects profile in Volumes of up to 5 L compared with 6% hetastarch in saline
-
Hextend, a physiologically balanced plasma Expander for large Volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group.
1999Co-Authors: Tj Gan, Bennett-guerrero E, Phillips-bute B, Wakeling H, Dm Moskowitz, Olufolabi Y, Sn Konstadt, Bradford C, Ps Glass, Sj MachinAbstract:UNLABELLED: Hextend (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with alternatives, such as albumin or 6% hetastarch in saline. In a prospective, randomized, two-center study (n = 120), we compared the efficacy and safety of Hextend versus 6% hetastarch in saline (HES) for the treatment of hypovolemia during major surgery. Patients at one center had a blood sample drawn at the beginning and the end of surgery for thromboelastographic (TEG) analysis. Hextend was as effective as HES for the treatment of hypovolemia. Patients received an average of 1596 mL of Hextend: 42% received >20 mL/kg up to a total of 5000 mL. No patient received albumin. Hextend-treated patients required less intraoperative calcium (4 vs 220 mg; P < 0.05). In a subset analysis of patients receiving red blood cell transfusions (n = 56; 47%), Hextend-treated patients had a lower mean estimated blood loss (956 mL less; P = 0.02) and were less likely to receive calcium supplementation (P = 0.04). Patients receiving HES demonstrated significant prolongation of time to onset of clot formation (based on TEG) not seen in the Hextend patients (P < 0.05). No Hextend patient experienced a related serious adverse event, and there was no difference in the total number of adverse events between the two groups. The results of this study demonstrate that Hextend, with its novel buffered, balanced electrolyte formulation, is as effective as 6% hetastarch in saline for the treatment of hypovolemia and may be a safe alternative even when used in Volumes up to 5 L. IMPLICATIONS: Hextend (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and a physiological level of glucose. It is as effective as 6% hetastarch in saline for the treatment of hypovolemia but has a more favorable side effects profile in Volumes of up to 5 L compared with 6% hetastarch in saline
-
hextend registered sign a physiologically balanced plasma Expander for large Volume use in major surgery a randomized phase iii clinical trial
Anesthesia & Analgesia, 1999Co-Authors: Tong J Gan, Sn Konstadt, Elliott Bennettguerrero, Barbara Phillipsbute, H Wakeling, David M Moskowitz, Y Olufolabi, C Bradford, Peter S A Glass, Sj MachinAbstract:Hextend[registered sign] (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with a
Sn Konstadt - One of the best experts on this subject based on the ideXlab platform.
-
Hextend (R), a physiologically balanced plasma Expander for large Volume use in major surgery: A randomized phase III clinical trial
LIPPINCOTT WILLIAMS & WILKINS, 1999Co-Authors: Tj Gan, Bennett-guerrero E, Phillips-bute B, Wakeling H, Dm Moskowitz, Olufolabi Y, Sn Konstadt, Bradford C, Glass Psa, Sj MachinAbstract:Hestend((R)) (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with alternatives, such as albumin or 6% hetastarch in saline. In a prospective, randomized, two-center study (n = 120), we compared the efficacy and safety of Hextend((R)) versus 6% hetastarch in saline (HES) for the treatment of hypovolemia during major surgery. Patients at one center had a blood sample drawn at the beginning and the end of surgery for thromboelastographic (TEG) analysis. Hextend((R)) was as effective as HES for the treatment of hypovolemia. Patients received an average of 1596 mt of Hestend((R)): 42% received >20 mL/kg up to a total of 5000 mt. No patient received albumin. Hextend((R))-treated patients required less intraoperative calcium (4 vs 220 mg; P < 0.05). In a subset analysis of patients receiving red blood cell transfusions (n = 56; 47%), Hextend((R))-treated patients had a lower mean estimated blood loss (956 mt less; P = 0.02) and were less likely to receive calcium supplementation (P = 0.04). Patients receiving HES demonstrated significant prolongation of time to onset of clot formation (based on TEG) not seen in the Hextend((R)) patients (P < 0.05). No Hextend((R)) patient experienced a related serious adverse event, and there was no difference in the total number of adverse events between the two groups. The results of this study demonstrate that Hextend((R)), with its novel buffered, balanced electrolyte formulation, is as effective as 6% hetastarch in saline for the treatment of hypovolemia and may be a safe alternative even when used in Volumes up to 5 L. Implications: Hextend((R)) (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and a physiological level of glucose. It is as effective as 6% hetastarch in saline for the treatment of hypovolemia but has a more favorable side effects profile in Volumes of up to 5 L compared with 6% hetastarch in saline
-
Hextend, a physiologically balanced plasma Expander for large Volume use in major surgery: a randomized phase III clinical trial. Hextend Study Group.
1999Co-Authors: Tj Gan, Bennett-guerrero E, Phillips-bute B, Wakeling H, Dm Moskowitz, Olufolabi Y, Sn Konstadt, Bradford C, Ps Glass, Sj MachinAbstract:UNLABELLED: Hextend (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with alternatives, such as albumin or 6% hetastarch in saline. In a prospective, randomized, two-center study (n = 120), we compared the efficacy and safety of Hextend versus 6% hetastarch in saline (HES) for the treatment of hypovolemia during major surgery. Patients at one center had a blood sample drawn at the beginning and the end of surgery for thromboelastographic (TEG) analysis. Hextend was as effective as HES for the treatment of hypovolemia. Patients received an average of 1596 mL of Hextend: 42% received >20 mL/kg up to a total of 5000 mL. No patient received albumin. Hextend-treated patients required less intraoperative calcium (4 vs 220 mg; P < 0.05). In a subset analysis of patients receiving red blood cell transfusions (n = 56; 47%), Hextend-treated patients had a lower mean estimated blood loss (956 mL less; P = 0.02) and were less likely to receive calcium supplementation (P = 0.04). Patients receiving HES demonstrated significant prolongation of time to onset of clot formation (based on TEG) not seen in the Hextend patients (P < 0.05). No Hextend patient experienced a related serious adverse event, and there was no difference in the total number of adverse events between the two groups. The results of this study demonstrate that Hextend, with its novel buffered, balanced electrolyte formulation, is as effective as 6% hetastarch in saline for the treatment of hypovolemia and may be a safe alternative even when used in Volumes up to 5 L. IMPLICATIONS: Hextend (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and a physiological level of glucose. It is as effective as 6% hetastarch in saline for the treatment of hypovolemia but has a more favorable side effects profile in Volumes of up to 5 L compared with 6% hetastarch in saline
-
hextend registered sign a physiologically balanced plasma Expander for large Volume use in major surgery a randomized phase iii clinical trial
Anesthesia & Analgesia, 1999Co-Authors: Tong J Gan, Sn Konstadt, Elliott Bennettguerrero, Barbara Phillipsbute, H Wakeling, David M Moskowitz, Y Olufolabi, C Bradford, Peter S A Glass, Sj MachinAbstract:Hextend[registered sign] (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with a
Tong J Gan - One of the best experts on this subject based on the ideXlab platform.
-
Perioperative clinical and economic outcomes associated with replacing first-generation high molecular weight hydroxyethyl starch (Hextend®) with low molecular weight hydroxyethyl starch (Voluven®) at a large medical center
Perioperative Medicine, 2015Co-Authors: Raquel R Bartz, William D White, Tong J GanAbstract:Background Several plasma Volume Expander alternatives exist to enhance intravascular Volume status in patients undergoing surgery. The optimal intravascular Volume Expander in the perioperative setting is currently unknown. Low molecular weight hetastarch, Voluven® (130/0.4), may have a better safety profile than high molecular weight hetastarch, Hextend® (450/0.7). We examined the clinical and cost outcomes of converting from Hextend® to Voluven® in a large tertiary medical center. Methods Using a large electronic database, we retrospectively compared two different time periods (2009 and 2010) where the availability of semisynthetic colloids changed. Perioperative and postoperative outcomes including the use of red blood cells (RBC), platelets and coagulation factors, length of stay in the postoperative acute care unit (PACU), intensive care unit and hospital, as well as 30-day and 1-year mortality were compared. In addition, direct acquisition costs of all intraoperative and PACU colloids and crystalloid use were determined. Results A total of 4,888 adult subjects were compared of which 1,878 received Hextend® (pre-conversion) and 2,759 received Voluven® (post-conversion) during two separate 7-month periods within 1 year apart, with the remainder receiving Plasmanate. The patients were similar in terms of patient demographics, preoperative comorbidities, ASA status, emergency surgery, types of surgery, intraoperative, and PACU times. In unadjusted outcomes, patients in the Hextend® group received more lactated Ringer’s than in the Voluven® group (2,220 + 1,312 vs. 1,946 ± 1,097 ml; P
-
hextend registered sign a physiologically balanced plasma Expander for large Volume use in major surgery a randomized phase iii clinical trial
Anesthesia & Analgesia, 1999Co-Authors: Tong J Gan, Sn Konstadt, Elliott Bennettguerrero, Barbara Phillipsbute, H Wakeling, David M Moskowitz, Y Olufolabi, C Bradford, Peter S A Glass, Sj MachinAbstract:Hextend[registered sign] (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with a
Y Olufolabi - One of the best experts on this subject based on the ideXlab platform.
-
hextend registered sign a physiologically balanced plasma Expander for large Volume use in major surgery a randomized phase iii clinical trial
Anesthesia & Analgesia, 1999Co-Authors: Tong J Gan, Sn Konstadt, Elliott Bennettguerrero, Barbara Phillipsbute, H Wakeling, David M Moskowitz, Y Olufolabi, C Bradford, Peter S A Glass, Sj MachinAbstract:Hextend[registered sign] (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with a
H Wakeling - One of the best experts on this subject based on the ideXlab platform.
-
hextend registered sign a physiologically balanced plasma Expander for large Volume use in major surgery a randomized phase iii clinical trial
Anesthesia & Analgesia, 1999Co-Authors: Tong J Gan, Sn Konstadt, Elliott Bennettguerrero, Barbara Phillipsbute, H Wakeling, David M Moskowitz, Y Olufolabi, C Bradford, Peter S A Glass, Sj MachinAbstract:Hextend[registered sign] (BioTime, Inc., Berkeley, CA) is a new plasma Volume Expander containing 6% hetastarch, balanced electrolytes, a lactate buffer, and physiological levels of glucose. In preclinical studies, its use in shock models was associated with an improvement in outcome compared with a
